prostate cancer screening screening process used detect undiagnosed prostate cancer men without signs abnormal prostate tissue cancer found early may easier treat cure unclear early detection reduces mortality screening precedes diagnosis subsequent treatment digital rectal examination dre one screening tool prostate manually assessed wall rectum second screening tool measurement prostatespecific antigen psa blood evidence remains insufficient determine whether screening psa dre reduces mortality prostate cochrane review concluded psa screening results statistically significant difference prostate cancerspecific american studies determined high bias european studies included review low bias one reported significant reduction prostate cancerspecific mortality psa screening dre assessed review dre assessed recent guidelines recommended decision whether screen based shared men informed risks benefits american society clinical oncology recommends screening discouraged expected live less ten years longer life expectancy decision made person question general conclude based recent research uncertain whether benefits associated psa testing prostate cancer screening worth harms associated screening subsequent unnecessary prostate biopsies used diagnose prostate cancer done asymptomatic men therefore used infection prostate biopsy occurs death occurs result biopsy prostate biopsy guided magnetic resonance imaging improved diagnostic accuracy prostatespecific antigen psa secreted epithelial cells prostate gland detected sample psa present small quantities serum men healthy prostates often elevated presence prostate cancer prostate psa unique indicator prostate cancer may also detect prostatitis benign prostatic united states preventive services task force uspstf draft adjusted prior opposition psa suggests shared decisionmaking regarding screening healthy males years final recommendation age group states screening done wish screening remains screening psa associated number harms including overdiagnosis increased prostate biopsy associated harms increased anxiety unneeded evidence surrounding prostate cancer screening indicates may cause little difference hand men diagnosed even die prostate cancer highgrade ie aggressive prostate conversely argue psa testing men young many men would screened find one cancer many men would treatment cancer would progress lowrisk prostate cancer always require immediate treatment may amenable active psa test prove existence prostate cancer varying levels antigen due digital rectal examination dre healthcare provider slides gloved finger rectum presses prostate check size detect lumps accessible side examination suggests anomalies psa test performed elevated psa level found followup test review recommended primary care screening prostate cancer dre due lack evidence effectiveness uspstf recommends digital rectal examination screening tool due lack evidence although dre long used diagnose prostate cancer controlled studies shown reduction morbidity mortality prostate cancer detected dre american urological association stated men aged could find evidence support continued use dre firstline screening test however men referred elevated psa dre may useful secondary study krilaviciute et al examined effectiveness dre standalone screening test prostate cancer young men germany age found dre much lower detection rate prostate cancer compared psa screening therefore authors recommend use dre screening test prostate cancer young men provide improvement detection compared psa screening prostate biopsies considered gold standard detecting prostate infection possible mri guided techniques improved diagnostic accuracy biopsies done rectum peniscitation needed transrectal ultrasonography trus advantage fast minimally invasive better mri evaluation superficial also gives details layers rectal wall accurate useful staging primary rectal cancer mri better visualization locally advanced stenosing cancers staging perirectal lymph nodes trus mri capable trus small field view trus improve diagnosis anorectal mri used screening suggests model potentially minimizes unnecessary prostate biopsies maximizing biopsy discusscitation needed despite concerns cost mri scans compared longterm cost burden psatrus biopsybased standard care imaging model found costeffectivedubious discusscitation needed mri imaging used patients previous negative biopsy psa continues consensus determined mritargeted biopsy techniques petct imaging become relatively short period time gold standard restaging recurrent prostate cancer clinical centers imaging modality likely become standard imaging modality staging intermediatetohigh risk primary prostate potential guide therapy facilitate accurate prostatic biopsy theranostic paradigm petct imaging critical detecting prostate specific membrane antigenavid disease may respond targeted local recurrence petmr petct combination mpmr psma petct may potentially helpful locating cancer combined multiparametric mri mpmri primary prostate prostate multiparametric mr imaging mpmri helpful evaluating recurrence primary prostate cancer following number biomarkers prostate cancer exist researchers korea institute science technology kist developed urinary multi marker sensor ability measure trace amounts biomarkers naturally voided correlation clinical state sensing signals form urinary multi markers analyzed two machine learning algorithms random forest neural network algorithms provided monotonic increase screening performance number biomarkers increased best combination biomarkers algorithms able screen prostate cancer patients screening prostate cancer continues generate debate among clinicians broader lay publications authored governmental nongovernmental medical organizations continue debate publish recommendations one six men diagnosed prostate cancer lifetime screening may result overdiagnosis overtreatment prostate though death rates prostate cancer continue decline men diagnosed prostate cancer united states died result death rates prostate cancer declined steady rate since cancers prostate lung bronchus colorectum accounted newly diagnosed cancers american men prostate cancer constituting cases screening prostate cancer varies state indicates differences use screening prostate cancer well variations locales cases prostate cancer african american men incidence african american men less likely receive standard therapy prostate cancer discrepancy may indicate receive higher quality cancer treatment survival rates would similar prostate cancer also extremely heterogeneous prostate cancers indolent would never progress clinically meaningful stage left undiagnosed untreated mans lifetime hand subset potentially lethal screening identify within window opportunity thus psa screening advocated means detecting highrisk potentially lethal prostate cancer understanding lowerrisk disease discovered often need treatment may amenable active screening prostate cancer controversial cost uncertain longterm benefits horan echos sentiment private medical institutes mayo clinic likewise acknowledge organizations vary recommendations shouldnt get psa screening test conclude ultimately whether psa test something youll decide discussing doctor considering risk factors weighing personal study europe resulted small decline death rates concluded men would need treated save one life men treated would unable ever function sexually would require frequent trips needed aggressive marketing screening tests drug companies also generated controversy advocacy testing american urological one commentator observed prudent use single psa determination baseline biopsy cancer treatment reserved significant psa changes time clinical manifestations mandating immediate therapy absolute levels psa rarely meaningful relative change psa levels time provides insight definitive proof cancerous condition necessitating therapy screening psa began european randomized study screening prostate cancer erspc initiated early researchers concluded psabased screening reduce rate death prostate cancer created high risk overdiagnosis ie men would need screened additional cases prostate cancer would need treated prevent one death prostate cancer within study published european journal cancer october documented prostate cancer screening reduced prostate cancer mortality percent utilizing control group men northern ireland psa screening infrequent research showed substantial reduction prostate cancer deaths compared men psa tested part erspc study published new england journal medicine found period screening reduce death rate men former screening proponents including stanford university come routine testing february american cancer society urged caution using test american college preventive medicine concluded insufficient evidence recommend routine study nhs comparison arm protect cap part prostate testing cancer treatment protect study randomized gp practices men aged centers cities britain usual care prostate cancer screening psa biopsy psa comparison arm yet report early httpsenwikipediaorgwikiprostatecancerscreening